Clinical trial NCT06823700: Safety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU
Official title: A Prospective, Multicenter, Single Arm Study to Evaluate the Safety and Effectiveness of Shenqi Transcatheter Mitral Valve Clips Delivery System and Steerable Guide Catheters in Patients with Functional Mitral Regurgitation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Functional Mitral Regurgitation
Lead sponsor: Shanghai Shenqi Medical Technology Co., Ltd
Sponsor class: INDUSTRY
First posted: 2025-02-12
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Device: SQ-Kyrin Transcatheter Mitral Valve Repair System
Primary purpose: TREATMENT

Brief summary: The investigation objective of this study is to evaluate the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in the population of FMR patients and the accessories devices when used in conjunction with the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter.

Detailed description: The primary objective is to verify the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. In the treatment of patients with moderate-severe (3 +) or severe (4 +) FMR whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

Eligibility criteria: Inclusion Criteria:

1. Participant who has provided written informed consent for the investigation.
2. Age ≥18 years.
3. Patients diagnosed with FMR.
4. MR severity is (functional) ≥3+ as determined by transthoracic echocardiography (TTE).
5. LVEF ≥20% to ≤60%.
6. Symptom status: NYHA functional class II to IV despite a stable maximally tolerated GDMT regimen as per guidelines.
7. According to the judgment of local cardiology team, subjects have undergone adequate treatment for at least 30 days (preferably 90 days) based on the criteria recommended in the heart failure guidelines.
8. Subject fulfils FMR anatomy selection criteria.
9. According to the judgment of the local Cardiovascular medical-surgery team, subjects who have high or prohibitive risk for open heart surgery.
10. Left ventricular end-systolic diameter (LVESD)≤70mm.
11. The MR beam mainly originates from the A2/P2 area.
12. Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets\>10mm.
13. Mitral valve effective orifice area (EOA) ≥ 4.0cm2.
14. No obvious calcification of main grasp mitral valve leaflets.
15. Patient anatomy allows atrial septum approach.

Exclusion Criteria:

1. Life expectancy \<1 year due to non-cardiac conditions or heart failure deemed suitable for palliative treatment.
2. Hypotension (systolic pressure \<90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support.
3. UNOS status 1 heart transplantation or prior orthotopic heart transplantation.
4. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.
5. Fixed pulmonary artery systolic pressure \>70 mm Hg.
6. Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
7. Mitral valve anatomy which may preclude proper device treatment.
8. Mitral valve area \< 4.0 cm2 (if new device therapy may further decrease the mitral orifice area).
9. Any prior mitral valve surgery or transcatheter mitral valve procedure.
10. Stroke or transient ischemic event within 30 days before enrolment.
11. Modified Rankin ≥ Scale 4 disability.
12. Severe symptomatic carotid stenosis (\>70% by ultrasound).
13. Need for emergent or urgent intervention for any reason or any planned cardiac intervention within the next 12 months.
14. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 1 month before enrolment.
15. Untreated clinically significant coronary artery disease requiring revascularization.
16. Any percutaneous cardiovascular intervention, cardiovascular intervention, or carotid intervention within 30 days
17. Tricuspid valve disease requiring intervention or severe or more tricuspid regurgitation.
18. Aortic valve disease requiring intervention or any concomitant treatment.
19. Need for any cardiovascular intervention (other than for MV disease).
20. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
21. Active endocarditis.
22. Active infections requiring current antibiotic therapy.
23. Subjects in whom transoesophageal echocardiography is contraindicated or high risk.
24. Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits.
25. Patient unable or unwilling to provide written, informed consent before study enrolment.
26. Pregnant woman or woman planning to become pregnant.
27. Patients with severe liver, renal or pulmonary disease, which in investigator opinion may have an impact on patient safety.
28. Clinically significant lab abnormalities which in investigator opinion may have an impact on patient safety.

Primary outcomes:
measure: Number of patients with composite measures- All-cause death and recurrent hospitalizations due to heart failure
timeFrame: 12 months
Secondary outcomes:
measure: Technical success rate
timeFrame: immediately after intervention
measure: Device success rate
timeFrame: 30 days
measure: Procedural success rate
timeFrame: 30 days
measure: The rate of New York Heart Association (NYHA) heart function class I or II
timeFrame: On the day of discharge, 30 days, 6 months, and 12 months
measure: Improvement in quality of life from baseline
timeFrame: 12 months
measure: Rate of MR 2+ or less than 2+
timeFrame: 30 days, 6 months, and 12 months
measure: Change from baseline to discharge in MR severity assessed by echocardiography.
timeFrame: On the day of discharge
measure: Rate of hospitalization for heart failure
timeFrame: 30 days, 6 months, and 12 months
measure: Improvement by ≥ 50m in 6-minute walk distance from baseline
timeFrame: 12 months
measure: Improvement in left ventricular end-diastolic volume (LVEDV) from baseline
timeFrame: 12 months
measure: Incidence of all-cause mortality
timeFrame: 30 days, 6 months, and 12 months
measure: Cardiovascular-related mortality
timeFrame: 30 days, 6 months, and 12 months
measure: Incidence of major adverse events
timeFrame: 30 days and 12 months
Other outcomes:
Locations:
city: Valladolid
country: Spain
facility: Hospital Clínico Universitario de Valladolid
Study officials:
affiliation: Hospital Clínico Universitario de Valladolid
name: Ignacio J Amat-Santos, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: